Pelvital raises $2.32m to advance commercialisation of Flyte device

Retrieved on: 2024-04-23 17:58:58

Tags for this article:

Click the tags to see associated articles and topics

Pelvital raises $2.32m to advance commercialisation of Flyte device. View article details on hiswai:

Summary

Pelvital raised additional funds to commercialize its Flyte device, an FDA-approved treatment for stress urinary incontinence, leveraging business intelligence insights from GlobalData for strategic decisions. The article was shared on LinkedIn.

Article found on: www.medicaldevice-network.com

View Original Article